Schonfeld Strategic Advisors LLC Decreases Holdings in Rezolute, Inc. (NASDAQ:RZLT)

Schonfeld Strategic Advisors LLC lessened its stake in shares of Rezolute, Inc. (NASDAQ:RZLT) by 79.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 71,932 shares of the company’s stock after selling 272,368 shares during the period. Schonfeld Strategic Advisors LLC’s holdings in Rezolute were worth $352,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in RZLT. JPMorgan Chase & Co. bought a new position in Rezolute during the third quarter worth about $42,000. Charles Schwab Investment Management Inc. boosted its position in Rezolute by 65.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock worth $112,000 after purchasing an additional 9,000 shares during the period. American Century Companies Inc. boosted its position in Rezolute by 62.1% during the fourth quarter. American Century Companies Inc. now owns 64,591 shares of the company’s stock worth $316,000 after purchasing an additional 24,742 shares during the period. Geode Capital Management LLC boosted its position in Rezolute by 5.2% during the fourth quarter. Geode Capital Management LLC now owns 517,014 shares of the company’s stock worth $2,535,000 after purchasing an additional 25,413 shares during the period. Finally, ExodusPoint Capital Management LP bought a new position in Rezolute during the fourth quarter worth about $277,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Analysts Set New Price Targets

RZLT has been the subject of a number of research reports. JMP Securities increased their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Rezolute in a research report on Monday, April 28th. Craig Hallum upgraded shares of Rezolute to a “strong-buy” rating in a research report on Tuesday, February 4th. Finally, Guggenheim restated a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $26.43.

Insider Activity at Rezolute

In related news, CEO Nevan C. Elam bought 12,302 shares of the stock in a transaction that occurred on Thursday, March 27th. The shares were acquired at an average cost of $2.85 per share, with a total value of $35,060.70. Following the completion of the purchase, the chief executive officer now directly owns 224,119 shares of the company’s stock, valued at $638,739.15. This trade represents a 5.81% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Wladimir Hogenhuis bought 10,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was bought at an average cost of $4.70 per share, for a total transaction of $47,000.00. Following the completion of the purchase, the director now directly owns 77,267 shares of the company’s stock, valued at $363,154.90. This represents a 14.87% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 39,060 shares of company stock valued at $130,694 over the last three months. 18.39% of the stock is owned by corporate insiders.

Rezolute Trading Down 0.8%

RZLT stock opened at $3.69 on Monday. The firm has a 50 day moving average of $3.25 and a 200-day moving average of $4.36. The firm has a market capitalization of $223.37 million, a P/E ratio of -3.02 and a beta of 1.01. Rezolute, Inc. has a 12 month low of $2.22 and a 12 month high of $6.19.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. Sell-side analysts predict that Rezolute, Inc. will post -0.93 EPS for the current year.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.